Comparing Entrada Therapeutics (NASDAQ:TRDA) & BioLineRx (NASDAQ:BLRX)

Entrada Therapeutics (NASDAQ:TRDAGet Free Report) and BioLineRx (NASDAQ:BLRXGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Entrada Therapeutics and BioLineRx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entrada Therapeutics 14.42% 9.73% 4.80%
BioLineRx N/A -325.10% -86.48%

Valuation & Earnings

This table compares Entrada Therapeutics and BioLineRx’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entrada Therapeutics $129.01 million 3.87 -$6.68 million $0.63 23.48
BioLineRx $4.80 million 10.33 -$60.61 million ($0.76) -0.82

Entrada Therapeutics has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Entrada Therapeutics and BioLineRx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics 0 0 2 0 3.00
BioLineRx 0 0 1 0 3.00

Entrada Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 41.99%. BioLineRx has a consensus price target of $21.00, suggesting a potential upside of 3,287.10%. Given BioLineRx’s higher probable upside, analysts plainly believe BioLineRx is more favorable than Entrada Therapeutics.

Risk and Volatility

Entrada Therapeutics has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Insider and Institutional Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Entrada Therapeutics beats BioLineRx on 10 of the 13 factors compared between the two stocks.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.